Vallejo-Vaz, Antonio JBray, SarahVilla, GuillermoBrandts, JuliaKiru, GaiaMurphy, JenniferBanach, MaciejDe Servi, StefanoGaita, DanGouni-Berthold, IoannaKees Hovingh, GJozwiak, Jacek JJukema, J WouterGabor Kiss, RobertKownator, SergeIversen, Helle KMaher, VincentMasana, LuisParkhomenko, AlexanderPeeters, AndréClifford, PiersRaslova, KatarinaSiostrzonek, PeterRomeo, StefanoTousoulis, DimitriosVlachopoulos, CharalambosVrablik, MichalCatapano, Alberico LPoulter, Neil RRay, Kausik KDA VINCI Study Investigators2023-05-032023-05-032022-05-14http://hdl.handle.net/10668/20496Low-density lipoprotein cholesterol (LDL-C) recommendations differ between the 2018 American College of Cardiology/American Heart Association (ACC/AHA) and 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines for patients with atherosclerotic cardiovascular disease (ASCVD) ( DA VINCI was a cross-sectional observational study of patients prescribed lipid-lowering therapy (LLT) across 18 European countries. Ten-year cardiovascular risk (CVR) was predicted among ASCVD patients receiving stabilized LLT. For patients with LDL-C ≥ 70 mg/dl, the absolute LDL-C reduction required to achieve an LDL-C of  Of the 2039 patients, 61% did not achieve LDL-C  In ASCVD patients, achieving ESC/EAS LDL-C goals could result in a 2% additional ARR over 10 years versus the ACC/AHA approach.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Atherosclerotic cardiovascular diseaseCardiovascular disease preventionCardiovascular riskLDL-CLipid-loweringStatinsresearch article35567726open access10.1007/s10557-022-07343-x1573-7241https://link.springer.com/content/pdf/10.1007/s10557-022-07343-x.pdf